Form D · Biotechnology
Turnstone Biologics Corp.
New York, NY · CIK 0001764974
Offering snapshot reported Jul 14, 2021 · SEC filing
- Reported sold
- $80M Offering amount: $80M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2021 | Initial | $79,999,979 | No comparison | Not reported | SEC filing |
| Jan 18, 2019 | Initial | $42,099,987 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-406191
Source: Form D, filed Jul 14, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brad Bolzon | Director |
| Michael Burgess | Director, Executive |
| Maura Campbell | Executive |
| Jerel Davis | Director |
| Sammy Farah | Director, Executive |
| Robert Gould | Director |
| Rishi Gupta | Director |
| Jane Henderson | Executive |
| Stefan Larson | Director |
| Patrick Machado | Director |
| Jose Manuel Otero | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
920 Broadway 16 Th Floor
New York, NY, 10010
New York, NY, 10010